Printer Friendly

LEECO ANNOUNCES 1991 RESULTS

 LEECO ANNOUNCES 1991 RESULTS
 SOUTHFIELD, Mich., April 3 /PRNewswire/ -- Leeco Diagnostics, Inc.


(NASDAQ: LECO) announced today the following fourth quarter and fiscal year-end 1991 results:
 LEECO DIAGNOSTICS, INC.
 Three months ended Dec. 31 1991 1990
 Total revenues $4,474,064 $3,916,839
 Net income (loss) (6,027,741) (682,796)
 Net income (loss) per share (1.06) (0.12)
 Weighted average number of shares 5,711,041 5,729,074
 Twelve months ended Dec. 31 1991 1990
 Total revenues $19,682,962 $16,199,879
 Net income (loss) (8,237,714) (2,176,485)
 Net income (loss) per share (1.44) (0.38)
 Weighted average number of shares 5,721,560 5,729,074
 Leeco's losses in 1991 were $8,237,714 compared to $2,176,485 in 1990. This loss includes a restructuring charge of approximately $5,000,000 accrued in the last quarter of 1991. Total revenues for 1991 increased by $3,487,083 from 1990. Revenues from U.S. operations declined by 36 percent while revenues from foreign operations increased by 57 percent, due to the acquisition of the Sclavo RIA product line. The decrease in Leeco's sales from U.S. operations is the result of the decline of revenues from the RIA, EIA and Preview product lines because of lack of new proprietary products and increased competition in the markets served by Leeco.
 In light of the continuing deterioration of the company's U.S. operating results which are related to the product sales decrease, high manufacturing costs in the U.S. facility and the difficulties encountered by the company in improving its technology to compete in the U.S. Physician Office market, a restructuring charge of $5,000,000 was recorded in 1991 as part of a restructuring plan.
 In order to preserve the company's ability to continue to seek new business opportunities in 1992, the company is phasing-out its U.S. business and has recently completed the sale of its RIA product line assets to another company. Additional sales of assets will be completed in early 1992.
 This restructuring will reduce the company's losses and we expect to report further developments in the second quarter of 1992.
 -0- 4/3/92
 /CONTACT: Rod N. Raynovich, president and CEO of Leeco Diagnostics, 313-353-2620/
 (LECO) CO: Leeco Diagnostics, Inc. ST: Michigan IN: AUT SU: ERN


SM-OS -- NY055 -- 4939 04/03/92 15:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 3, 1992
Words:398
Previous Article:ARAB NETWORK OF AMERICA TO USE SATCOM 2R FOR NEWS AND EVENTS
Next Article:IMM'S ULTRAPHONE SYSTEM IS OPERATIONAL IN CHINA AND UKRAINE


Related Articles
LEECO DIAGNOSTICS THIRD QUARTER RESULTS
MICHIGAN OTC CHANGES, PROVIDED BY FIRST OF MICHIGAN CORP., TODAY: DEC. 6, 1991
MICHIGAN OTC CHANGES, PROVIDED BY FIRST OF MICHIGAN CORP., TODAY: DEC. 9, 1991
LEECO ANNOUNCES RESTRUCTURING OF ITS U.S. DIAGNOSTIC OPERATIONS
LEECO DIAGNOSTICS TRANSFERS RIA PRODUCT LINE ASSETS TO BINAX
LEECO ANNOUNCES FIRST QUARTER RESULTS
LEECO DIAGNOSTICS ANNOUNCES RESTRUCTURING AND MERGER WITH ENDOGEN; SECOND QUARTER RESULTS
LEECO DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER RESULTS
LEECO ANNOUNCES 1992 RESULTS
ENDOGEN, INC. RAISES $3.075 MILLION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters